ARTICLE | Clinical News
AZD9291 regulatory update
April 28, 2014 7:00 AM UTC
AstraZeneca disclosed in its 1Q14 earnings that earlier this month FDA granted breakthrough therapy designation to AZD9291 to treat metastatic, EGFR T790M mutation-positive non-small cell lung cancer...